Abstracts tagged "Damage Index"

Abstract Number: 0343 • ACR Convergence 2022
Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Yann Nguyen¹, Benoît BLanchet², Murray Urowitz³, John Hanly⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Juanita Romero-Diaz⁷, Jorge Sanchez-Guerrero⁸, Ann E Clarke⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Veronique Le Guern²⁷, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁸, S. Sam Lim²⁹, Murat Inanc³⁰, Kenneth C Kalunian³¹, Soren Jacobsen³², Christine Peschken³³, Diane Kamen³⁴, Anca Askanase³⁵, Jill Buyon³⁶ and Nathalie Costedoat-Chalumeau³⁷, ¹AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ²Biologie du médicament-Toxicologie, AP-HP Centre – Hôpital Cochin, Université Paris Cité, Paris, France, Paris, ³University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶Hanyang University Medical Center, Seoul, Republic of Korea, ⁷Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁸Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁹University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Hôpital Cochin, Paris, France, ²⁸Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁹Emory University, Atlanta, GA, ³⁰Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ³¹University of California San Diego School of Medicine, La Jolla, ³²Rigshospitalet, Copenhagen, Denmark, ³³University of Manitoba, Winnipeg, MB, Canada, ³⁴Medical University of South Carolina, Charleston, SC, ³⁵Columbia University Medical Center, New York, NY, ³⁶NYU Grossman School of Medicine, New York, NY, ³⁷Inserm DR Paris 5, Paris, France
Background/Purpose: The efficacy of antimalarials, especially hydroxychloroquine (HCQ), in preventing flares of systemic lupus erythematosus (SLE) is well demonstrated, but its effectiveness is impaired by…
Abstract Number: 0541 • ACR Convergence 2022
Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors
Tara Tofighi, Jiandong Su and Zahi Touma, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…
Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0982 • ACR Convergence 2022
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Jordan Jacquez¹, Lisa Zhu¹, Manpreet Singh¹, Caroline Siegel², Lori Sahakian¹, Brian Skaggs¹, Jennifer Grossman¹ and Maureen McMahon¹, ¹University of California Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated benefit in multiple outcomes in systemic lupus erythematosus (SLE), including disease activity, flare rates, survival, and thrombotic events. Previous studies,…
Abstract Number: 1528 • ACR Convergence 2022
Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
Janet Pope¹, Susanna Proudman², Wendy Stevens³, Joerg Henes⁴, Rozeta Simonovska⁵, Margarida Alves⁶ and Yannick Allanore⁷, ¹University of Western Ontario, London, ON, Canada, ²Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, ⁴Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
Abstract Number: 1562 • ACR Convergence 2022
Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
Yeliz Yagiz Ozogul¹, Yesim Ozguler², Didar Ucar³, Ugur Uygunoglu⁴, Zekayi Kutlubay⁵, Vedat Hamuryudan⁶ and gulen Hatemi⁷, ¹Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Neurology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Dermatology, Istanbul, Turkey, ⁶Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful…
Abstract Number: 1602 • ACR Convergence 2022
Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis
Simon Rauber¹, Hashem Mohammadian², Chrstian Schmidkonz³, Armin Atzinger³, Maria Gabriella Raimondo¹, Hannah Labinsky⁴, Christoph Treutlein², Johannes Knitza¹, Simone Maschauer², Frank Roemer⁵, Olaf Prante², Torsten Kuwert³, Juan Canete⁶, Georg Schett⁷ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Erlangen, Germany, ³Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁶Unidad de Artritis Hospital Clinic, Barcelona, Spain, ⁷Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…
Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Gustavo Balbi¹, Yasaman Ahmadzadeh², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Chary lopez-pedrera¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Cecilia Nalli¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Giuseppe Barilaro²⁰, Jason Knight²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan², Danieli De Andrade¹ and on Behalf of APS ACTION², ¹University of São Paulo, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Clínic Barcelona - Hospital Universitari, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 1298 • ACR Convergence 2020
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Maria Schletzbaum¹, Nnenna Ezeh², Trevor McKown³, Shivani Garg⁴ and Christie Bartels⁵, ¹University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, ³William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁴UW Madison, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…
Abstract Number: 1393 • ACR Convergence 2020
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
Miriam Retuerto¹, Jose Luis Rosales², Maria Martin¹, Beatriz Joven¹ and Patricia E Carreira¹, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospiten Rambla, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…
Abstract Number: 2036 • ACR Convergence 2020
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Ariane Barbacki¹, Murray Baron², Mianbo Wang³, Yuqing Zhang⁴, Mandana Nikpour⁵ and Ada Man⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
Abstract Number: 0267 • ACR Convergence 2020
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Beatriz Tejera Segura¹, Irene Altabás González², Iñigo Rúa-Figueroa³, Natalia Pérez Veiga⁴, Victor del Campo Pérez⁵, Alejandro Olivé-Marqués⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo-Alén⁸, Juan Ovalles-Bonilla⁹, Antonio Fernandez-Nebro¹⁰, Raul Menor Almagro¹¹, Eva Tomero Muriel¹², N. Del-val-del-amo¹³, Maria Esther Uriarte¹⁴, VM Martínez Taboada¹⁵, Jose Luis Andreu Sanchez¹⁶, Alina Lucica Boteanu¹⁷, Francisco Javier Narváez¹⁸, A Morasat¹⁹, Carlos Montilla Morales²⁰, JM Senabre Gallego²¹, Blanca Hernández Cruz²², Mariano Andrés²³, Eva Salgado Pérez²⁴, Mercedes Freire-González²⁵, Sergio Ramon Machin Garcia¹, Clara Moriano²⁶, Lorena Expósito²⁷, Clara E. Perez-Velasquez²⁸, ML Velloso-Feijoo²⁹, Ana Paula Cacheda³⁰, Nuria Lozano Rivas³¹, Gema Bonilla³², Marta Arévalo³³, Inmaculada Jimenez³⁴, VE Quevedo-Vila³⁵, Francisco Manero-Ruiz³⁶, Paloma García de la Peña³⁷, TR Vázquez-Rodríguez³⁸, J Ibáñez-Ruan³⁹, Tatiana Cobo-Ibañez⁴⁰ and Jose Maria Pego-Reigosa⁴¹, ¹Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, ⁵Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, ⁶Hospital Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰University of Malaga, Malaga, Spain, ¹¹Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹³Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁴Hospital Universitario Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ¹⁸Hospital Bellvitge, BARCELONA, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²⁰Hospital Universitario de Salamanca, Salamanca, Spain, ²¹Hospital Marina Baixa, Alicante, Spain, ²²Universidad de Sevilla, Sevilla, Spain, ²³Hospital General Universitario de Alicante, Alicante, Spain, ²⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ²⁵CHU Coruña, Coruña, Spain, ²⁶Complejo Asistencial Universitario de León, León, Spain, ²⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Valme, Sevilla, Spain, ³⁰Hospital son LLátzer, Palma de Mallorca, Spain, ³¹Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, ³²Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ³³Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³⁴Hospital Clínico San Ceciio Granada, Granada, Spain, ³⁵Hospital Comarcal de Monforte, Lugo, Spain, ³⁶Hospital Universitario Miguel Servet, Zaragoza, Spain, ³⁷Hospital HM, Madrid, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Hospital Povisa, Vigo, Pontevedra, Spain, ⁴⁰Hospital Infanta Sofia, Madrid, Spain, ⁴¹University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].